In this months biopharm I read about the spiralling cost of biomedical research. New drug approvals have flattened out in recent years, particularly for new molecular entities. As far as man power is concerned, over the last few years there has been an unprecedented increase in the number of bioinformaticians and there is no dearth of lead molecules. However clinical research personal failed to catch up and manufacturers are under pressure to find out more efficient ways to develop medical products. I think very soon the initial phases of clinical studies may become computer simulations and the actual human studies will become more targeted.
Latest posts by Bell Eapen (see all)
- Kedro for multimodal machine learning in healthcare - January 25, 2023
- Using OpenFaaS containers in Kubeflow - December 14, 2022
- Six things data scientists in healthcare should know - November 3, 2021